Erlotinib
3337
Summary
Erlotinib is an EGFR tyrosine kinase inhibitor. It’s used to treat advanced, non-small cell lung cancer with an EGFR mutation. An adverse side effect of Erlotinib is the development of rashes on the face and back.
Key Points
- Erlotinib
- Mechanism
- EGFR tyrosine kinase inhibitor
- Clinical use
- Non-small cell lung cancer
- Advanced Non-small cell lung cancer with an EGFR mutation
- Non-small cell lung cancer
- Adverse effects
- Rash (nonspecific)
- Mechanism